Pancreatic Ductal Adenocarcinoma
Conditions
Brief summary
The goal of this observational study is to test the application value of 3D bioprinting technology in personalized treatment of pancreatic cancer. The main questions it aims to answer are: * Can 3D bioprinting technology be successfully applied to establish preclinical models of pancreatic cancer? * Can 3D bioprinted preclinical models of pancreatic cancer be applied to personalized treatment of pancreatic cancer? Participants will have tumor tissue collected to extract primary tumor cells for the establishment of in vitro preclinical models, which will be used for drug sensitivity testing.
Interventions
None listed
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* More than 18 years old * Diagnosed as colorectal cancer with or without liver metastases before * Pathologically proven colorectal cancer after surgery
Exclusion criteria
* History of other malignancies or serious medical conditions * Inability to provide independent informed consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of Drug Sensitivity in In Vitro Tumor Models with Clinical Response in Patients | From enrollment to end within 2 weeks | 1. Evaluation of the efficacy of neoadjuvant therapy in clinical response using the internationally recognized Response Evaluation Criteria in Solid Tumors (RECIST) 1.1: Stable Disease (SD) and Partial Response (PR) are considered indicators of chemotherapy sensitivity (good response), while Progressive Disease (PD) is considered indicative of chemotherapy resistance (poor response). 2. Drug sensitivity testing results were assessed using standardized IC50 values. The standardized IC50 values were treated as the testing variables, while the clinical response to chemotherapy was designated as the state variable. The ROC curves for both variables were analyzed, and the area under the curve (AUC) was calculated to assess their correlation. To analyze the correlation between the drug testing results and clinical prognosis, linear regression analysis was performed to evaluate the correlation between standardized IC50 values and patients' progression-free survival (PFS) values. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival time (PFS) | Up to 2 years. | The time from the start of postoperative adjuvant therapy to recurrence or death. |
Countries
China
Contacts
Primary ContactYilei Mao
Backup ContactHang Sun
Outcome results
None listed